Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.33 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3375539 | 1.00 | DDB1 (0.36) | DDB1CRBNADRB3ADRA2BADRA2C | |
| SCHEMBL13757915 | 0.95 | DDB1 (0.36) | DDB1CRBNADRB3ADRA2BADRA2C | |
| SCHEMBL3375346 | 0.95 | DDB1 (0.36) | DDB1CRBNADRB3ADRA2BADRA2C | |
| SCHEMBL13435737 | 0.94 | DDB1 (0.37) | DDB1CRBNADRB3ADRA2BADRA2C | |
| SCHEMBL13798458 | 0.93 | DDB1 (0.34) | DDB1CRBNADRB3ADRA2BADRA2C | |
| SCHEMBL13798452 | 0.93 | DDB1 (0.34) | DDB1CRBNADRB3ADRA2BADRA2C | |
| SCHEMBL13798448 | 0.93 | DDB1 (0.34) | DDB1CRBNADRB3ADRA2BADRA2C | |
| SCHEMBL13798450 | 0.92 | DDB1 (0.35) | DDB1CRBNADRB3ADRA2BADRA2C | |
| SCHEMBL13798318 | 0.92 | DDB1 (0.34) | DDB1CRBNADRB3ADRA2BADRA2C | |
| SCHEMBL13798426 | 0.91 | DDB1 (0.33) | DDB1CRBNADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2177523-A1 | Novel macrocyclic inhibitors of hepatitis c virus replication | Intermune, Inc. (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090155209-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090155209-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. | 2009-06-18 | — | — | US | disclosed |
| WO-2008137779-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | DDB1 144/4885CRBN 2720/4885ADRB3 4323/4885 |
| US-20090155209-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | DDB1 499/4885CRBN 1884/4885ADRB3 4329/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | DDB1 144/4885CRBN 2720/4885ADRB3 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.